Kuros Biosciences Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Chris Fair

Chief Executive Officer (CEO)

CHF1.3m

Compensación total

Porcentaje del salario del CEO	24.6%
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	5.7yrs

Actualizaciones recientes de la dirección

Shareholders May Find It Hard To Justify Increasing Kuros Biosciences AG's (VTX:KURN) CEO Compensation For Now

Apr 12

What We Learned About Kuros Biosciences' (VTX:KURN) CEO Pay

Nov 17

Recent updates

Why Investors Shouldn't Be Surprised By Kuros Biosciences AG's (VTX:KURN) 35% Share Price Surge

Apr 11

Some Confidence Is Lacking In Kuros Biosciences AG (VTX:KURN) As Shares Slide 29%

Jan 03

Companies Like Kuros Biosciences (VTX:KURN) Are In A Position To Invest In Growth

Dec 17

We Think Kuros Biosciences (VTX:KURN) Can Afford To Drive Business Growth

Sep 17

Market Cool On Kuros Biosciences AG's (VTX:KURN) Revenues

Jun 28

Here's Why We're Not At All Concerned With Kuros Biosciences' (VTX:KURN) Cash Burn Situation

May 03

Companies Like Kuros Biosciences (VTX:KURN) Are In A Position To Invest In Growth

Jun 11

Shareholders May Find It Hard To Justify Increasing Kuros Biosciences AG's (VTX:KURN) CEO Compensation For Now

Apr 12

Reflecting on Kuros Biosciences' (VTX:KURN) Share Price Returns Over The Last Five Years

Mar 02

What We Learned About Kuros Biosciences' (VTX:KURN) CEO Pay

Nov 17

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Chris Fair en comparación con los beneficios de Kuros Biosciences?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	CHF1m	CHF329k	-CHF14m
Sep 30 2023	n/a	n/a	-CHF15m
Jun 30 2023	n/a	n/a	-CHF16m
Mar 31 2023	n/a	n/a	-CHF15m
Dec 31 2022	CHF36k	n/a	-CHF15m
Sep 30 2022	n/a	n/a	-CHF13m
Jun 30 2022	n/a	n/a	-CHF11m
Mar 31 2022	n/a	n/a	-CHF9m
Dec 31 2021	CHF36k	n/a	-CHF8m

Compensación vs. Mercado: La compensación total de Chris($USD1.47M) está por encima de la media de empresas de tamaño similar en el mercado Swiss ($USD915.55K).

Compensación vs. Ingresos: La compensación de Chris ha aumentado mientras la empresa no es rentable.

CEO

Chris Fair (53 yo)

less than a year

Permanencia

CHF1,337,700

Compensación

Mr. Christopher T. Fair, also known as Chris, serves as the Chief Executive Officer At Kuros Biosciences AG since October 2023 and serves as Director since April 17, 2024. He was the Chief Operating Office...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Christopher Fair	CEO & Director	less than a year	CHF1.34m	sin datos
Daniel Geiger	Chief Financial Officer	less than a year	sin datos	sin datos
Sjoerd Musters	COO & GM of BV	less than a year	sin datos	sin datos
Joost de Bruijn	President of Innovation and Strategy & Executive Director	less than a year	CHF873.70k	0% CHF 0
Philippe Saudan	Chief Development Officer	7.8yrs	sin datos	sin datos
John Griffin	Chief Commercial Officer	6.1yrs	sin datos	sin datos
Katherine Sage	Senior Vice President of Medical & Clinical Affairs	less than a year	sin datos	sin datos
Virginia Jamieson	Consultant	6yrs	sin datos	sin datos

0.8yrs

Permanencia media

54.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de KURN no se considera experimentado ( 0.7 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Christopher Fair	CEO & Director	less than a year	CHF1.34m	sin datos
Joost de Bruijn	President of Innovation and Strategy & Executive Director	5.9yrs	CHF873.70k	0% CHF 0
Clemens van Blitterswijk	Chairman	6.9yrs	CHF92.60k	1.98% CHF 5.4m
Oliver Walker	Independent Non-Executive Director	5.9yrs	CHF73.80k	sin datos
Cato Laurentin	Member of Advisory Board	no data	sin datos	sin datos
Ralph Müller	Member of Advisory Board	no data	sin datos	sin datos
Norbert Boos	Member of Advisory Board	no data	sin datos	sin datos
Thomas Steffen	Member of Advisory Board	no data	sin datos	sin datos
Andrew Sama	Member of Strategic Advisory Board	5.7yrs	sin datos	sin datos
Richard Allen	Member of Strategic Advisory Board	5.7yrs	sin datos	sin datos
Alpesh Patel	Member of Strategic Advisory Board	5.7yrs	sin datos	sin datos
Kornelis Poelstra	Member of Strategic Advisory Board	5.7yrs	sin datos	sin datos

5.7yrs

Permanencia media

55.5yo

Promedio de edad

Junta con experiencia: La junta directiva de KURN se considera experimentada (5.6 años de antigüedad promedio).

Kuros Biosciences Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Kuros Biosciences AG Approves Board of Director and Committee Changes

Less than half of directors are independent

Kuros Biosciences AG, Annual General Meeting, Jun 08, 2022

Less than half of directors are independent

Shareholders May Find It Hard To Justify Increasing Kuros Biosciences AG's (VTX:KURN) CEO Compensation For Now

What We Learned About Kuros Biosciences' (VTX:KURN) CEO Pay

Recent updates

Kuros Biosciences AG Approves Board of Director and Committee Changes

Why Investors Shouldn't Be Surprised By Kuros Biosciences AG's (VTX:KURN) 35% Share Price Surge

Kuros Biosciences AG to Report Fiscal Year 2023 Results on Mar 13, 2024

New minor risk - Financial data availability

Kuros Biosciences Receives US FDA 510K Clearance for Magnetos Granules for Interbody Use and Regulatory Clearance of Magnetos Granules and Magnetos Putty in New Zealand

Some Confidence Is Lacking In Kuros Biosciences AG (VTX:KURN) As Shares Slide 29%

Companies Like Kuros Biosciences (VTX:KURN) Are In A Position To Invest In Growth

Kuros Biosciences Receives FDA Clearance for Use of Magnetos in Interbody Spinal Cages

We Think Kuros Biosciences (VTX:KURN) Can Afford To Drive Business Growth

Market Cool On Kuros Biosciences AG's (VTX:KURN) Revenues

Full year 2022 earnings released: CHF0.43 loss per share (vs CHF0.23 loss in FY 2021)

Less than half of directors are independent

Kuros Biosciences AG has completed a Follow-on Equity Offering in the amount of CHF 6 million.

Kuros Biosciences’ MagnetOs Bone Graft Successfully Achieves Three Key Milestones

First half 2022 earnings released: CHF0.11 loss per share (vs CHF0.003 loss in 1H 2021)

Kuros Biosciences AG, Annual General Meeting, Jun 08, 2022

Here's Why We're Not At All Concerned With Kuros Biosciences' (VTX:KURN) Cash Burn Situation

Less than half of directors are independent

Kuros Biosciences’S Magnetos Flex Matrix Receives Clearance by U.S. Food and Drug Administration for Spinal Indications

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Kuros Biosciences Ag Announces Its Magnetos Granules Cleared by FDA for Expanded Spinal Indications

Kuros Biosciences Publishes First-In-Human Clinical Data for Fibrin-PTH in Treatment of Open Tibial Shaft Fractures

Kuros Biosciences to Showcase New Magnetos Products At Nass 2021 Annual Meeting

Kuros Biosciences Announces Publication of Data on Magnetos in eCM Journal Linking Moa to Enhanced Predictable Bone Regeneration

Companies Like Kuros Biosciences (VTX:KURN) Are In A Position To Invest In Growth

Shareholders May Find It Hard To Justify Increasing Kuros Biosciences AG's (VTX:KURN) CEO Compensation For Now

Full year 2020 earnings released: CHF0.47 loss per share (vs CHF0.71 loss in FY 2019)

Kuros Biosciences AG to Complete the Phase II Clinical Study of Fibrin-PTH in Spine

Kuros Biosciences Announces MagnetOs Sales and Distribution Agreements Across Northern Europe

Reflecting on Kuros Biosciences' (VTX:KURN) Share Price Returns Over The Last Five Years

New 90-day high: CHF2.30

What We Learned About Kuros Biosciences' (VTX:KURN) CEO Pay

New 90-day low: CHF2.10

Earnings released

New 90-day high - CHF2.47

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad